Money

Found 78,484 articles

• Affimed Reports 2022 Financial Results and Operational Progress

  3/23/2023

  Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported financial results for the year ended December 31, 2022, and provided an update on clinical and corporate progress.

• TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

  3/23/2023

  TCR² Therapeutics Inc. announced fourth quarter and full-year 2022 financial results and provided a corporate update.

• Helius Medical Technologies, Inc. Announces Distribution of Series B Preferred Stock to Holders of its Class A Common Stock Intended to Facilitate a Reverse Stock Split, if Necessary

  3/23/2023

  Helius Medical Technologies, Inc. announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series B Preferred Stock, par value $0.001 per share, for each outstanding share of Helius Class A common stock held of record on April 3, 2023.

• Valneva Reports Full Year 2022 Results and Provides Corporate Updates

  3/23/2023

  Valneva SE a specialty vaccine company, reported its consolidated financial results for the year ending December 31, 20224 and provided corporate updates.

• Applied Therapeutics Reports Fourth Quarter and Year-end 2022 Financial Results

  3/23/2023

  Applied Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.

• Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023

  3/23/2023

  Atreca, Inc. announced that it will host a conference call and webcast on Wednesday, March 29, 2023, at 4:30 p.m. EDT to report financial results and provide an update on its discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of ATRC-101.

• Octapharma USA Grant Supports PANS/PANDAS Education Event at NHIA Conference March 27 in Washington, D.C.

  3/23/2023

  Octapharma USA has provided a grant for an educational program on pediatric acute-onset neuropsychiatric syndrome (PANS) and PANDAS, a subset of PANS associated with strep, to be held during the National Home Infusion Association (NHIA) Annual Conference scheduled for March 25 – 27 in Washington, D.C.

• Lunaphore Raises CHF 40M in the First Close of Series D Funding led by EGS Beteiligungen AG

  3/23/2023

  Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, announced today that it has completed CHF 40M in Series D1 funding.

• Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress

  3/23/2023

  Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today is providing a business update and reporting financial results for the year ended December 31, 2022.

• 

  Pfizer-Backed Flare Seeks Transcription Factor Therapies with $123M Series B

  3/22/2023

  Flare Therapeutics closed Wednesday an oversubscribed Series B funding round, counting $123 million in earnings, which it will use to advance its lead precision oncology asset FX-909 in urothelial cancer.

• Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing

  3/22/2023

  Oculis Holding AG announces that it will ring the Nasdaq opening bell to celebrate its public listing on the Nasdaq Stock Market earlier this month.

• Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

  3/22/2023

  Acer Therapeutics Inc. announced that it has entered into a definitive agreement for the purchase and sale of 2,920,306 shares of the Company’s common stock at a purchase price of $0.916 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.

• Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer’s Disease

  3/22/2023

  Cognito Therapeutics announced today a $73M Series B financing round led by FoundersX Ventures with participation from all existing investors.

• JanOne Sells Legacy Business ARCA Recycling to Concentrate on Growing BioPharm Businesses

  3/22/2023

  JanOne announced that on March 9, 2023 they entered into a Stock Purchase Agreement with VM7, a Delaware corporation, under which VM7 agreed to acquire all of the outstanding equity interests of ARCA Recycling, Inc, Customer Connexx LLC and ARCA Canada Inc. Virland Johnson, who has served as ARCA Recycling's CFO and COO for several years is the principal of VM7.

• Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities

  3/22/2023

  Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $3 million in grant funding to eight organizations to provide services to communities disproportionately impacted by HIV in rural areas in the United States.

• EpiBiologics Launches with $50 million Series A Financing to Advance Next-Generation Protein Degradation Platform

  3/22/2023

  EpiBiologics launched today with $50 million in Series A funding.

• CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023

  3/22/2023

  CytomX Therapeutics, Inc., a leader in the field of conditionally activated, localized biologics, announced that it will report full year 2022 financial results on Monday, March 27, 2023, after the close of U.S. markets.

• Tempest Reports Year End 2022 Financial Results and Provides Business Update

  3/22/2023

  Tempest Therapeutics, Inc. reported financial results for the year ended December 31, 2022 and provided a corporate update.

• CONMED Corporation Announces Annual Meeting of Stockholders - March 22, 2023

  3/22/2023

  CONMED Corporation announced that its Annual Meeting of Stockholders will be held on Wednesday, May 24, 2023, at 1:30 p.m. ET at its corporate headquarters at 11311 Concept Boulevard, Largo FL and through the internet virtually.

• Poxel will Report its 2022 Full Year Results on March 23, 2023

  3/22/2023

  POXEL SA announced it will report its 2022 Full year results on March 23, 2023, before market opening.